Citations

Clear

16280 citation(s) found for "Yu, David".

Neuropsychiatric symptoms cluster and fluctuate over time in behavioral variant frontotemporal dementia
Morrow, Christopher B. , Eldaief, Mark C. , Rezaii, Neguine, Wong, Bonnie , McGinnis, Scott, Darby, Ryan, Staffaroni, Adam M. , Pascual, Belén , Masdeu, Joseph C. , Tsapkini, Kyrana , Huey, Edward D. , Fisher, Daniel , Balaji, Akshata, Sah, Eric , Rascovsky, Katya, Ghoshal, Nupur , Domoto‐Reilly, Kimiko , Kornak, John , Onyike, Chiadi U. , Huang, Eric J. , Yokoyama, Jennifer S. , Paulson, Henry L. , Wong, Bonnie , Damme, Philip Van , Barmada, Sami J. , Rezaii, Neguine , Sah, Eric , Paulson, Henry L , Van Damme, Philip , Pascual, Belen , Yokoyama, Jennifer , Domoto-Reilly, Kimiko , Barmada, Sami , Morrow, Christopher , Kamath, Vidyulata , Dickerson, Bradford Clark , Lapid, Maria I. , Rojas, Julio C., Masdeu, Joseph C , Pantelyat, Alexander , Balaji, Akshata, Litvan, Irene

Mayo Clinic

Psychiatry and Clinical Neurosciences | March 13, 2025 | Volume: 79 | Issue: 6 | Pages: 327-335

10.1111/pcn.13810 | PMID 40079430 Get It

Aim Cognitive and behavioral phenomena define behavioral variant frontotemporal dementia (bvFTD), but neuropsychiatric symptoms (NPS) outside the core criteria are common throughout the illness. Identifying how NPS cluster in bvFTD may guide development of future therapies. Methods Participants ( n = 354) with sporadic and genetic bvFTD were enrolled in the ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration Consortium. Dementia stage was defined as early (CDR® plus NACC FTLD ≤1) or advanced (CDR® plus NACC FTLD ≥1). Baseline and annual follow‐up visit data were analyzed to compare NPS across stages of bvFTD. Psychiatric states were captured using the Neuropsychiatric Inventory‐Questionnaire and Clinician Judgment of Symptoms. Polychoric cluster analysis was used to describe NPS clusters. Results NPS were highly prevalent (≥90%) in early and late bvFTD. Four NPS clusters were identified based on magnitude of factor loadings: affective, disinhibited, compulsive, and psychosis. Neuropsychiatric symptoms fluctuated across visits. In the affective cluster, depression showed the least visit‐to‐visit stability. In the disinhibited cluster, elation showed the least stability. Symptoms in the psychosis and compulsive clusters (hallucinations, delusions, obsessions/compulsions, and hyperorality) were largely stable, persisting from visit‐to‐visit in more than 50% of cases. Symptoms in the affective and disinhibited cluster were associated with the highest caregiver burden, while symptoms in the obsessive cluster were associated with the most functional impairment. Conclusion NPS in bvFTD are frequent and cluster into four discrete groups. The fluctuating nature of some NPS in bvFTD suggests that they may not be reliable markers of disease progression or stage.
A mixed-methods study assessing the performance of a clinical decision support tool for Clostridioides difficile testing for patients receiving laxatives
Peaper, David R. , Rathod, Shardul N , Sussman, L. Scott , Azar, Marwan M. , Murdzek, Christina, Roberts, Scott C. , Tichy, Eric M. , Topal, Jeffrey , Kashyap, Nitu , McManus, Dayna , Topal, Jeffrey E , Martinello, Richard A , Azar, Marwan M

Mayo Clinic

Infection Control & Hospital Epidemiology | March 13, 2025 | Volume: 46 | Issue: 5 | Pages: 497-503

10.1017/ice.2025.30 | PMID 40079209 Get It

Abstract Objective: To better understand clinicians’ rationale for ordering testing for C. difficile infection (CDI) for patients receiving laxatives and the impact of the implementation of a clinical decision support (CDS) intervention. Design: A mixed-methods, case series was performed from March 2, 2017 to December 31, 2018. Setting: Yale New Haven Hospital, a 1,541 bed tertiary academic medical center. Participants: Hospitalized patients ≥ 18 years old, and clinicians who were alerted by the CDS. Intervention: CDS was triggered in real-time when a clinician sought to order testing for CDI for a patient who received one or more doses of laxatives within the preceding 24 hours. Results: A total of 3,376 CDS alerts were triggered during the 21-month study period from 2,567 unique clinician interactions. Clinicians bypassed the CDS alert 74.5% of the time, more frequent among residents (48.3% bypass vs. 39.9% accept) and advanced practice providers (APPs) (34.9% bypass vs. 30.6% accept) than attendings (11.3% bypass vs. 22.5% accept). Ordering clinicians noted increased stool frequency/output (48%), current antibiotic exposure (34%), and instructions by an attending physician to test (28%) were among the most common reasons for overriding the alert and proceeding with testing for CDI. Conclusions: Testing for CDI despite patient laxative use was associated with an increased clinician concern for CDI, patient risk for CDI, and attending physician instruction for testing. Attendings frequently accepted CDS guidance while residents and APPs often reinstated CDI test orders, suggesting a need for greater empowerment and discretion when ordering tests.
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025
Greenberg, P, Stone, Richard M. , Al‐Kali, Aref , Bennett, John M. , Borate, Uma , Brunner, Andrew M. , Chai‐Ho, Wanxing , Curtin, Peter , Gaensler, Karin, Gahvari, Zhubin, Garcia-Manero, Guillermo, Jacoby, Meagan A., Keel, Sioḃán , Khanal, Rashmi, Maness, Lori J., McMahon, Christine M. , Odenike, Olatoyosi , Osman, Afaf, Sallman, David A. , Sayar, Hamid , Shallis, Rory M. , Tanaka, Tiffany , Kovach, Emily, Nguyen, Jamie , Hochstetler, Cindy, Osman, Afaf E.G. , Osman, Afaf E G , Abaza, Yasmin , Anand, Sarah , Ball, Brian J. , Dezern, Amy Elizabeth , Garcia‐Manero, Guillermo , Griffiths, Elizabeth A. , Haque, Tamanna Zohra , Jonas, Brian A. , Kishtagari, Ashwin , Madanat, Yazan F. , McCurdy, Shannon , Reddy, Vishnu , Singh, Abhay , Thota, Swapna , Kovach, Emily

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 12, 2025 | Volume: 23 | Issue: 3 | Pages: 66-75

10.6004/jnccn.2025.0013 | PMID 40073835 Get It

The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and comprehensive care of patients with MDS based on a review of recent clinical evidence that has led to important advances in treatment or has yielded new information on biologic factors that may have prognostic significance in MDS. The multidisciplinary panel of MDS experts is convened at least on an annual basis. During the annual meeting, the panel evaluates new and emerging data to inform their recommendations. These NCCN Guidelines Insights review the recent updates, including treatment recommendations both for lower-risk and higher-risk MDS, preference stratification of therapeutic agents, and emerging data on novel therapeutics.
Acute sympathetic activation blunts the hyperemic and vasodilatory response to passive leg movement in young healthy males
Hanson, Brady E. , Lee, Joshua F., Garten, Ryan S. , Barrett‐O’Keefe, Zachary , Layec, Gwenaël , Ruple, Bradley A. , Richardson, Russell S. , Trinity, Joel D. , Trinity, Joel D , Wray, David Walter

Mayo Clinic

Physiological Reports | March 12, 2025 | Volume: 13 | Issue: 5 | Pages: No page available

10.14814/phy2.70180 | PMID 40017052 Get It

AbstractHeightened muscle sympathetic nerve activity (MSNA) contributes to impaired vasodilatory capacity and vascular dysfunction associated with aging and cardiovascular disease. The contribution of elevated MSNA to the vasodilatory response during passive leg movement (PLM) is not fully understood. This study tested the hypothesis that elevated MSNA diminishes the vasodilatory response to PLM in healthy young males (n = 11, 25 ± 2 yr). Post exercise circulatory occlusion (PECO) following 2 min of isometric handgrip (HG) exercise performed at 25% (ExPECO 25%) and 40% (ExPECO 40%) maximum voluntary contraction was used to incrementally engage the metaboreceptors and augment MSNA. Control trials were performed without PECO (ExCON 25% and ExCON 40%) to account for changes due to HG exercise. PLM was performed 2 min after exercise and hemodynamics were assessed. MSNA was recorded by microneurography in the peroneal nerve (n = 8). Measures of MSNA (i.e., burst incidences) increased during ExPECO 25% (+15 ± 5 burst/100 bpm) and ExPECO 40% (+22 ± 4 burst/100 bpm) and returned to pre‐HG levels during ExCON trials. Leg vascular conductance (vasodilation) during PLM was reduced by 16% and 44% during ExPECO 25% and ExPECO 40%, respectively. These findings indicate elevated MSNA attenuates the vasodilatory response to PLM and the magnitude of reduction in vasodilation during PLM is graded with the degree of sympathoexcitation.
Prevalence of cytopenia(s) and somatic variants in patients with DDX41 mutant germline predisposition syndrome
Kusne, Yael , Badar, Talha , Marando, Ludovica , Mangaonkar, Abhishek A. , Finke, Christy M. , Foran, James M. , Al‐Kali, Aref , Palmer, Jeanne , Yi, Cecilia Y. Arana , Gangat, Naseema , Viswanatha, David S., Litzow, Mark R. , Patnaik, Mrinal M. , Mangaonkar, Abhishek A. , Foran, James M , Arana Yi, Cecilia , Alkhateeb, Hassan B , Gangat, Naseema , Viswanatha, David, Badar, Talha , Lasho, Terra L. , Yi, Cecilia Arana , Alkhateeb, Hassan B. , Chlon, Timothy M. , Ferrer, Alejandro

Mayo Clinic

British Journal of Haematology | March 12, 2025 | Volume: 206 | Issue: 4 | Pages: 1109-1120

10.1111/bjh.20018 | PMID 40040251 Get It

SummaryGermline variants in DDX41 (DDX41MT‐germline predisposition syndrome [GPS]) are associated with predisposition to haematological malignancies (HM), including lymphoid and myeloid neoplasms (MN). We retrospectively analysed the clinical and molecular features of 195 patients diagnosed and treated at Mayo Clinic with DDX41MT‐GPS. Patients with germline DDX41 pathogenic variants (42.3%) and variants of unknown significance (VUS, 57.6%) were included. The median age was 68.6 years (16.2–93.4). Ninety‐two per cent were Caucasian, 64.1% were male and 30.8% had a family history of HM. There were 92 distinct germline variants among our cohort, and the most common was p.Met1? (15.9%), followed by p.Asp140Glyfs*2 (9.2%). Clinical diagnoses included asymptomatic carriers (10.2%), clonal cytopenia of undetermined significance (CCUS, 6.1%), myeloproliferative neoplasms (6.7%), myelodysplastic syndrome (40.5%), acute myeloid leukaemia (20.5%), lymphoid neoplasms (9.2%), plasma cell dyscrasias (6.1%) and solid tumours (22.5%). Patients with MN were older (median age 70 vs. 63.5 years) and more likely to be male (M:F ratio 2.3 vs. 1.0) and most patients (78.8%) with MN had a normal karyotype. The most common somatic variants involved DDX41 (34.4%), followed by TET2 (11.2%), DNMT3A (9.6%) and ASXL1 (9.2%). In summary, we have comprehensively described the spectrum of clinical phenotypes within the Mayo Clinic DDX41MT‐GPS cohort.
In Memoriam: Gary Mawe
Linden, David R. , Lavoie, Brigitte , Linden, D R

Mayo Clinic

The Journal of Physiology | March 12, 2025 | Volume: 603 | Issue: 6 | Pages: 1337-1346

10.1113/jp287402 Get It

Mental Health Diagnoses in Patients With Mycosis Fungoides and Potential Impact on Oncologic Outcomes
Howell, Jackson Neal , Mark, Bayarmaa , Wada, David A., Bowling, Marianne, Wei, Mei , Lloyd, Shane , Gaffney, David K. , Maity, Amit , LaRiviere, Michael J. , Rule, William G., Grant, Jonathan D., Deshmukh, Vikrant , Date, Ankita , Hashibe, Mia, Howell, Jackson N , Lloyd, Shane L , Tao, Randa , Newman, Michael

Mayo Clinic

Cancer Medicine | March 11, 2025 | Volume: 14 | Issue: 5 | Pages: No page available

10.1002/cam4.70577 | PMID 40052836 Get It

ABSTRACTBackgroundWe investigated mental health diagnoses (MHDs) in mycosis fungoides (MF) patients compared to the general population, evaluated risk factors, and studied survival outcomes in a large population database.MethodsMF patients from the Utah Cancer Registry diagnosed from 2001 to 2014 were matched with up to five general population individuals from the Utah Population Database. MHDs were retrospectively tracked in both populations (median follow‐up = 6.67 years). Risk factors for new MHDs among MF patients were studied using the Cox proportional hazards model. Overall survival (OS) and disease‐specific survival (DSS) were assessed using Kaplan–Meier analysis.ResultsThe incidence of anxiety disorders (HR = 1.99, 95% CI [1.16, 3.42]) and delirium/dementia disorders (HR = 2.43, 95% CI [1.05, 5.63]) was higher among MF patients than the matched general population. Among MF patients, Charlson Comorbidity Index (CCI) ≥ 2 and BMI < 18 kg/m2 were risk factors for new anxiety disorders. Radiation therapy, CCI ≥ 2, and female gender were risk factors for new delirium/dementia disorders. The 15‐year OS was worse for MF patients with versus without an MHD (36% vs. 81%, HR 2.62, 95%CI [1.24, 5.65]). The 15‐year DSS also worsened for MF patients with versus without an MHD (63% vs. 97%, HR 6.55, 95%CI [1.64, 26.2]).ConclusionsMF patients developed anxiety and delirium/dementia disorders at rates above the general population, and MHDs correlated with worse DSS and OS. Careful mental health monitoring may be an actionable step towards improving health‐related quality of life in this population.
Clinical Outcomes and Treatment Strategies of Adult Transplant‐Associated Thrombotic Microangiopathy: External Validation of Harmonizing Definitions and High‐Risk Criteria
Acosta‐Medina, Aldo A. , Sridharan, Meera , Moyer, Ann M. , Leung, Nelson , Willrich, Maria Alice V. , Kassis, Rabee, Kohorst, Mira A. , Matin, Aasiya , Mangaonkar, Abhishek A. , Litzow, Mark R. , Dingli, David , Alkhateeb, Hassan B. , Leung, Nelson , Willrich, Maria A , Wolf, Robert, Manasrah, AlMothana , Durani, Urshila , Hefazi, Mehrdad , Kenderian, Saad Sirop , Mangaonkar, Abhishek A. , Shah, Mithun V , Litzow, Mark R. , Dingli, David , Alkhateeb, Hassan B , Sridharan, Meera , Acosta-Medina, Aldo A , Go, Ronald S. , Wolf, Robert Christian , Durani, Urshila , Hefazi, Mehrdad , Kenderian, Saad S. , Shah, Meera , Hogan, William J.

Mayo Clinic

American Journal of Hematology | March 11, 2025 | Volume: 100 | Issue: 5 | Pages: 830-839

10.1002/ajh.27651 | PMID 40047384 Get It

ABSTRACTTransplant‐associated thrombotic microangiopathy (TA‐TMA) is an endothelial dysfunction syndrome observed after allogeneic hematopoietic cell transplant (alloHCT). Our aim was to externally validate the impact of high‐risk features on the clinical outcomes of adult patients meeting the updated TA‐TMA harmonizing criteria. Between 2005 and 2022, 99 patients were diagnosed with TA‐TMA at Mayo Clinic Rochester (incidence 6.2%) after a median of 137 days post alloHCT (IQR: 34–283 days). The development of TA‐TMA was associated with an inferior overall survival posttransplant (HR: 3.8, 95% CI: 2.97–4.72). High‐risk features, including concomitant infection, acute graft‐versus‐host disease (GVHD), and organ dysfunction, were associated with poor survival, while LDH elevation was not associated with inferior outcomes. The most common treatment strategy for TA‐TMA was discontinuation of calcineurin or mTOR inhibitors in 80 (81%) patients. Thirty (37.5%) patients experienced worsening of GVHD with this strategy, of which 26 (86.7%) patients had died at last follow‐up. The most common cause of death among these patients was worsening GVHD (69%; n = 18), followed by infection (11%; n = 3), disease relapse (8%; n = 2), other/unknown causes (8%; n = 2), or TA‐TMA (4%; n = 1). Objective response rate (ORR) to initial treatment for the cohort was 56.6%. Eculizumab was used in 11 patients with an observed ORR of 70%, including 5 complete responses. In conclusion, TA‐TMA remains a significant contributor to non‐relapse mortality and is associated with worse survival following alloHCT. Not all high‐risk features, particularly LDH elevation, have consistently demonstrated a negative impact in adult cohorts. Patients with TA‐TMA may benefit from immune suppression dose adjustment, rather than a discontinuation, and the addition of complement‐directed therapy, particularly among high‐risk patients.
Longitudinal Outcomes in Pi*MZ Alpha-1 Antitrypsin–Deficient Individuals with Tobacco Smoking History from the SPIROMICS Cohort
Barjaktarević, Igor , Hixson, Roxana, Zhuang, Zian , Buhr, Russell G. , Tejwani, Vickram , Barr, R. Graham, Bateman, Lori A. , Bhatt, Surya P. , Bleecker, Eugene R. , Cooper, Christopher B., Fortis, Spyridon , Hansel, Nadia N. , Hoffman, Eric A. , Martinez, Fernando J., Meyers, Deborah A., Paine, Robert, Pirozzi, C.S. , Sandhaus, Robert A. , Tashkin, Donald P., Wells, J. Michael , Woodruff, Prescott G. , Ortega, Victor E. , Drummond, M Bradley , Fortis, Spyridon , Hoffman, Eric A , Wells, J Michael , Barjaktarevic, Igor , Buhr, Russell G , Bhatt, Surya P , Barr, R. Graham, Curtis, Jeffrey L. , Drummond, Michael , Ghosh, Auyon , Han, MeiLan King , Ohar, Jill , Meyers, Deborah A. , Strange, Charlie

Mayo Clinic

Annals of the American Thoracic Society | March 11, 2025 | Volume: 22 | Issue: 7 | Pages: 998-1008

10.1513/annalsats.202411-1209oc | PMID 40068143 Get It

Abstract Rationale Reliable data about the natural history of lung function decline in alpha-1 antitrypsin (AAT)-deficient Pi*MZ heterozygotes is largely missing. Objectives We hypothesized that, in adults with a tobacco smoking history, lung function deteriorates faster in Pi*MZ compared with the Pi*MM genotype. Methods We identified 1,856 Pi*MM and 79 Pi*MZ participants with ⩾20 pack-years tobacco smoking history from the SPIROMICS (Subpopulations and Intermediate Outcomes Measures in COPD Study) cohort by DNA sequencing and followed them over a median of 4.8 years, comparing radiographic and clinical characteristics between the two groups over time using regression models. Results Adjusted for age, sex, race, smoking pack-year history, and smoking status, Pi*MZ participants had a lower baseline percent predicted forced expiratory volume in 1 second (FEV1) (65.4% vs. 75.1%; difference 95% confidence interval [CI], −15.4% to −3.9%), more radiographic emphysema (&lt;−950 Hounsfield units%, 12.9% vs. 7.8%; difference 95% CI, 2.8% to 7.5%), and nonsignificantly lower lung density. In the longitudinal analysis, the FEV1 annual rate of decline was similar in both groups over the course of the study (−34.5 ml/yr vs. −34.6 ml/yr for Pi*MZ and Pi*MM; difference 95% CI, −16.9 to 17.1 ml/yr). There were no significant differences between Pi*MZ and Pi*MM individuals in the annualized change in lung density, emphysema, patient-reported outcomes, exacerbations, or survival. The proportion with faster FEV1 decline (annual loss ⩾40 ml) was similar in Pi*MZ and Pi*MM groups. In both groups, faster FEV1 decline was associated with more air trapping and small airway disease at baseline. In Pi*MZ only, faster decline was associated with higher blood eosinophil counts (310 vs. 220 cells/μl; difference 95% CI, 30 to 140 cells/μl). In the subgroup analysis limited to a small number of currently smoking participants, no significant differences in longitudinal outcomes were found. Conclusions Despite a lower FEV1 and more emphysema at enrollment, the longitudinal analysis did not demonstrate significantly greater lung function decline or lung density loss in Pi*MZ compared with Pi*MM participants with tobacco smoking history. Limited sample size and duration of longitudinal follow-up constrain generalizability of our findings, thus prohibiting the conclusion that longitudinal trajectories did not differ between these groups. However, our results may suggest that earlier life events could be responsible for more extensive lung disease at enrollment in Pi*MZ compared with Pi*MM tobacco-exposed individuals.
Strategic Development of a Larynx and Trachea Transplantation Program: The Mayo Clinic Arizona Experience
Zacharias, Stephanie R. C. , Grandjean, Danielle, Stearns, Elizabeth, Mour, Girish , Mour, Girish K , Lott, David G.

Mayo Clinic

Clinical Transplantation | March 11, 2025 | Volume: 39 | Issue: 3 | Pages: No page available

10.1111/ctr.70126 | PMID 40062927 Get It

ABSTRACTMedical advances have enabled the realization of vascularized composite allografts and to date have demonstrated reasonably successful graft survival rates. Larynx and Trachea Transplantation (LT) has long been contemplated as a therapeutic option for severe laryngeal trauma and patients following total laryngectomy. Progress has been limited most likely due to lack of awareness as an option, technical and surgical expertise, limited transplant centers worldwide, need for multidisciplinary engagement from hospital leadership, Otolaryngology, and transplant medicine to build a successful program. As one of the first programs to exist in the United States, we have had to create new pathways, develop new workflows, work with numerous regulatory bodies, educate many people about the need for an LT, and learn many lessons along the way. The objectives of this paper are to help others navigate the complexities of creating a new LT transplant program so that this important treatment option may become more available to patients worldwide. We will provide a checklist for developing an LT program and discuss our experiences with the strategic development of an LT transplant program in an academic medical institution.